In a filing, Perspective Therapeutics Inc revealed its Director HENSON HEIDI acquired Company’s shares for reported $0.1 million on Dec 04 ’24. In the deal valued at $3.85 per share,25,975 shares were bought. As a result of this transaction, HENSON HEIDI now holds 25,975 shares worth roughly $99484.25.
Then, Spoor Johan M. bought 8,000 shares, generating $30,132 in total proceeds. Upon buying the shares at $3.77, the CEO now owns 36,257 shares.
Before that, Williamson Robert F III bought 6,266 shares. Perspective Therapeutics Inc shares valued at $22,814 were divested by the Director at a price of $3.64 per share. As a result of the transaction, Williamson Robert F III now holds 430,058 shares, worth roughly $1.65 million.
BofA Securities downgraded its Perspective Therapeutics Inc [CATX] rating to a Neutral from a a Buy in a research note published on November 25, 2024; the price target was decreased to $5 from $24. A number of analysts have revised their coverage, including UBS’s analysts, who began to cover the stock in late October with a ‘”a Buy”‘ rating. Wedbush began covering CATX with “an Outperform” recommendation on October 01, 2024. Truist started covering the stock on September 25, 2024. It rated CATX as “a Buy”.
Price Performance Review of CATX
On Monday, Perspective Therapeutics Inc [AMEX:CATX] saw its stock fall -4.49% to $3.83. Over the last five days, the stock has gained 11.66%. Perspective Therapeutics Inc shares have risen nearly 20.06% since the year began. Nevertheless, the stocks have fallen -21.61% over the past one year. While a 52-week high of $19.05 was reached on 01/24/25, a 52-week low of $2.70 was recorded on 01/16/25. SMA at 50 days reached $4.16, while 200 days put it at $11.20.
Levels Of Support And Resistance For CATX Stock
The 24-hour chart illustrates a support level at 3.71, which if violated will result in even more drops to 3.60. On the upside, there is a resistance level at 4.03. A further resistance level may holdings at 4.23. The Relative Strength Index (RSI) on the 14-day chart is 51.17, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.30, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 33.61%. Stochastics %K at 76.66% indicates the stock is a holding.
How much short interest is there in Perspective Therapeutics Inc?
A steep rise in short interest was recorded in Perspective Therapeutics Inc stocks on 2024-12-31, dropping by -1.51 million shares to a total of 8.93 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 10.45 million shares. There was a decline of -16.95%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on July 25, 2024 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $24 price target.
